To include your compound in the COVID-19 Resource Center, submit it here.

Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck

BioCentury's roundup of preclinical news

By BioCentury Staff | Feb 7, 2020 | 1:58 AM GMT
Editor's note: Updated on Feb 8, 2020 at 4:00 AM GMT

Chinese team provides data for Gilead’s remdesivir against 2019-nCoV
A group from the Chinese Academy of Science’s Wuhan Institute of Virology and the Beijing Institute of Pharmacology and Toxicology showed that remdesivir reduced 2019-nCoV infection of monkey kidney cells with an EC50 of 0.77 μM and

Read the full 454 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE